Petros Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Petros Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Petros Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.22M, a 51.2% increase year-over-year.
  • Petros Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$4.73M, a 62.8% increase year-over-year.
  • Petros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$8.16M, a 59.3% increase from 2022.
  • Petros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$20M, a 123% decline from 2021.
  • Petros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$8.99M, a 56.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$4.73M -$2.22M +$2.33M +51.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$7.06M -$662K +$1.88M +74% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$8.94M -$2.16M -$778K -56.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$8.16M $318K +$4.54M Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$12.7M -$4.55M +$9.28M +67.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$22M -$2.55M -$735K -40.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$21.2M -$1.39M -$1.21M -695% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$20M -$4.22M +$3.96M +48.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$24M -$13.8M -$12.1M -715% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-15
Q2 2022 -$11.9M -$1.81M +$301K +14.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$12.2M -$174K -$3.18M -106% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$8.99M -$8.19M -$2.75M -50.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$6.24M -$1.7M +$1.6M +48.6% Jul 1, 2021 Sep 30, 2021 10-Q/A 2022-11-15
Q2 2021 -$7.84M -$2.11M +$3.65M +63.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$11.5M $3.01M +$9.09M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$20.6M -$5.44M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$3.3M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$5.76M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$6.08M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.